Making moves: Inovio, Veru, MindMed and more announce key new hires

Listen to the article 6 min This audio is auto-generated. Please let us know if you have feedback. Veru appoints new head of its US Infectious Disease Franchise ahead of potential COVID-19 EUA Joel Batten, executive vice president of Veru’s infectious disease franchise Retrieved from Veru Inc. on May 25, 2022 Who: Joel Batten joined … Read more

Pharmas can be ‘more than medicine’ by focusing on preventative care

Listen to the article 7 min This audio is auto-generated. Please let us know if you have feedback. If an ounce of prevention is worth a pound of cure, then pharmas face an existential quandary: In the business of selling medicines that treat disease, what happens when what’s best for patients is avoiding disease altogether? … Read more

First 90 Days: Syneos Health’s Michelle Keefe

Listen to the article 9 min This audio is auto-generated. Please let us know if you have feedback. Welcome to First 90 Days, a series dedicated to examining how pharma executives are planning for success in their new role. Today, we’re featuring a conversation with Michelle Keefe, Syneos Health’s new CEO, who approaches the role … Read more

The UK-based company that’s striving to overcome the limitations of T cell receptor innovation

Listen to the article 6 min This audio is auto-generated. Please let us know if you have feedback. When the FDA earlier this year approved the first T cell receptor (TCR) therapeutic to treat a solid tumor, the nod marked a turning point for the field of immunotherapies and personalized medicine. The approved product, Immunocore’s … Read more

Junior Party Broad Files Reply to Sigma-Aldrich Opposition to Substantive Preliminary Motion No. 1 in Interference No. 106,133

By Kevin E. Noonan — On December 3rd, Junior Party the Broad Institute, Harvard University, and MIT (collectively, Broad) filed its Substantive Preliminary Motion No. 1 in Interference No. 106,133 (which names Sigma-Aldrich as Senior Party), asking the Patent Trial and Appeal Board (PTAB) to substitute the interference Count, pursuant to the provisions of 37 … Read more

Doctors Gave Her Antipsychotics. She Decided to Live With Her Voices.

To back its position, the WHO highlights stark words from Thomas R. Insel, who from 2002 to 2015 was head of the National Institute of Mental Health, the largest funder of mental-health research in the world: “I spent 13 years at NIMH really pushing on the neuroscience and genetics of mental disorders, and when I … Read more

Tracking trends in healthcare, from tech to patient care

Listen to the article 7 min This audio is auto-generated. Please let us know if you have feedback. Every year, the Healthcare Businesswomen’s Association, a nonprofit organization whose core purpose is to further the advancement and impact of women in the healthcare business, honors a wide array of executives. Last week, we talked to some … Read more

Sigma-Aldrich Files Reply to Broad’s Opposition to Sigma’s Substantive Preliminary Motion No. 1 to Deny Priority Benefit in Interference No. 106,133

By Kevin E. Noonan — On December 3rd, Senior Party Sigma-Aldrich filed its Preliminary Motion No. 1 that asked the Board to deny the Broad Institute, Harvard University, and MIT (collectively, Broad) benefit of its US Provisional Application No. 61/736,527, filed December 12, 2012 (termed “P1”), pursuant to 37 CFR § 41.121(a)(1) and SO ¶¶ … Read more

A potential COVID-19 EUA could turn this small biotech into a household name

Listen to the article 7 min This audio is auto-generated. Please let us know if you have feedback. It’s not a done deal. But so far, all indications point to the probability of Veru, a small biotech, winning the latest Emergency Use Authorization from the FDA for a COVID-19 treatment. And if all goes well, … Read more

Ironwood Pharmaceuticals is charting a course to become a giant in GI

Listen to the article 7 min This audio is auto-generated. Please let us know if you have feedback. Rain, shine or blizzard, Tom McCourt always made a point to walk home through the streets of Cambridge, Mass., alongside his coworker at Ironwood Pharmaceuticals, then chief scientific officer, Mark Currie, during his early years as chief … Read more